[DOWNLOAD] Case Study: Dapivirine Vaginal Ring
Assess uterine contractility in human fresh tissue
In 2020, the DPV-VR received a positive opinion from the EMA, making it the first microbicide to do so. The EMA assessed evidence from hundreds of preclinical and clinical studies of dapivirine, including studies in human fresh tissue conducted by REPROCELL (Biopta).
Download this PDF case study, and learn more about:
REPROCELL's (Biopta) role in the development of the DPV-VR
How we used human fresh tissue to estimate uterine contractility
IPM's future plans for the DPV-VR